Clinical Trials Logo

Advanced Disease clinical trials

View clinical trials related to Advanced Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03879668 Completed - Advanced Disease Clinical Trials

Monitoring of Palliative Care Needs in Specialized Palliative Home Care Using the Electronic Version of the Integrated Palliative Care Outcome Scale

Palli-MONITOR
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

In palliative care, the Integrated Palliative Care Outcome Scale (IPOS) is widely used as a patient reported outcome measure (PROM) and covers patients' main concerns, common symptoms, patient and family distress, existential wellbeing, sharing feelings with family, information received, and practical concerns. The IPOS is validated for patients with advanced cancer or non-cancer disease and is available as patients and professional carer version. The implementation of a PROM in the home care setting is more challenging compared to the inpatient setting. Palli-MONITOR will develop, implement and test the feasibility of an internet-based real-time monitoring of palliative needs of patients with advanced diseases using the electronic version of IPOS (eIPOS) including a clinical decision support tool for specialist palliative home care. The project is conducted in two parts: 1. A pilot study to develop an electronical monitoring that is acceptable for both palliative patients and professionals of specialist palliative home care teams. 2. A feasibility study to implement and test eIPOS in specialist palliative home care teams.

NCT ID: NCT01209676 Completed - Melanoma Clinical Trials

IMCgp100 in Advanced Unresectable Melanoma

Start date: September 2010
Phase: Phase 0
Study type: Interventional

A phase 0, exploratory study of the pharmacodynamics of a single intratumoral dose of IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein, in subjects with advanced unresectable melanoma to assess the safety and pharmacodynamic properties of single intratumoral doses of IMCgp100 in the setting of advanced unresectable melanoma. Six patients will be enrolled to complete the study over approximately 12-15 months.